Dynavax Technologies Corp. (NASDAQ:DVAX) was up 2.9% on Thursday . The stock traded as high as $15.80 and last traded at $15.47, with a volume of 337,198 shares. The stock had previously closed at $15.04.

Several equities research analysts recently weighed in on DVAX shares. Zacks Investment Research raised Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Wednesday, May 25th. JPMorgan Chase & Co. cut Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $29.00 to $22.00 in a research note on Wednesday, April 27th. Cowen and Company reaffirmed a “buy” rating and issued a $60.00 price target on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Finally, Royal Bank Of Canada cut Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $48.00 to $17.00 in a research note on Wednesday, April 27th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $32.20.

The company’s market cap is $589.36 million. The company has a 50 day moving average price of $14.98 and a 200-day moving average price of $18.26.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.07. The firm earned $942 million during the quarter, compared to analyst estimates of $627 million. Equities analysts anticipate that Dynavax Technologies Corp. will post ($2.90) EPS for the current year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray purchased 2,750 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was purchased at an average cost of $15.57 per share, with a total value of $42,817.50. Following the purchase, the chief executive officer now owns 5,050 shares of the company’s stock, valued at $78,628.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several large investors have modified their holdings of DVAX. Trexquant Investment LP raised its stake in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares in the last quarter. Swiss National Bank raised its stake in shares of Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the period. Finally, California State Teachers Retirement System raised its stake in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares during the period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.